TD Private Client Wealth LLC Has $1.27 Million Holdings in West Pharmaceutical Services, Inc. (NYSE:WST)

TD Private Client Wealth LLC decreased its holdings in West Pharmaceutical Services, Inc. (NYSE:WST) by 3.1% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 4,237 shares of the medical instruments supplier’s stock after selling 137 shares during the quarter. TD Private Client Wealth LLC’s holdings in West Pharmaceutical Services were worth $1,272,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of the business. FMR LLC raised its position in shares of West Pharmaceutical Services by 199.4% in the third quarter. FMR LLC now owns 595,775 shares of the medical instruments supplier’s stock valued at $178,828,000 after buying an additional 396,780 shares in the last quarter. LGT Group Foundation bought a new stake in shares of West Pharmaceutical Services during the 2nd quarter valued at $68,854,000. Liontrust Investment Partners LLP acquired a new stake in shares of West Pharmaceutical Services during the 2nd quarter worth $64,196,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in shares of West Pharmaceutical Services by 21.8% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 683,350 shares of the medical instruments supplier’s stock worth $205,114,000 after purchasing an additional 122,361 shares in the last quarter. Finally, Champlain Investment Partners LLC raised its stake in West Pharmaceutical Services by 29.7% in the third quarter. Champlain Investment Partners LLC now owns 444,000 shares of the medical instruments supplier’s stock valued at $133,271,000 after purchasing an additional 101,710 shares in the last quarter. Institutional investors own 93.90% of the company’s stock.

West Pharmaceutical Services Stock Performance

West Pharmaceutical Services stock opened at $330.24 on Friday. The business has a 50 day moving average of $312.73 and a 200-day moving average of $311.84. The company has a debt-to-equity ratio of 0.07, a current ratio of 3.00 and a quick ratio of 2.23. West Pharmaceutical Services, Inc. has a 1 year low of $265.00 and a 1 year high of $413.70. The company has a market capitalization of $23.92 billion, a P/E ratio of 49.00, a P/E/G ratio of 25.16 and a beta of 1.01.

West Pharmaceutical Services (NYSE:WST) last released its quarterly earnings results on Thursday, October 24th. The medical instruments supplier reported $1.85 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.50 by $0.35. West Pharmaceutical Services had a net margin of 17.37% and a return on equity of 18.41%. The firm had revenue of $746.90 million during the quarter, compared to the consensus estimate of $709.62 million. During the same quarter last year, the firm earned $2.16 earnings per share. The company’s revenue for the quarter was down .1% on a year-over-year basis. On average, equities research analysts predict that West Pharmaceutical Services, Inc. will post 6.64 earnings per share for the current year.

West Pharmaceutical Services Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, November 20th. Stockholders of record on Wednesday, November 13th were paid a $0.21 dividend. This is a boost from West Pharmaceutical Services’s previous quarterly dividend of $0.20. The ex-dividend date was Wednesday, November 13th. This represents a $0.84 annualized dividend and a dividend yield of 0.25%. West Pharmaceutical Services’s dividend payout ratio is presently 12.46%.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on WST shares. Wolfe Research started coverage on shares of West Pharmaceutical Services in a research note on Friday. They set a “peer perform” rating on the stock. Bank of America boosted their price objective on shares of West Pharmaceutical Services from $350.00 to $355.00 and gave the company a “buy” rating in a research report on Friday. Finally, UBS Group raised West Pharmaceutical Services from a “neutral” rating to a “buy” rating and raised their target price for the company from $350.00 to $390.00 in a report on Thursday. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $437.75.

Insider Transactions at West Pharmaceutical Services

In other news, VP Charles Witherspoon sold 703 shares of the stock in a transaction on Tuesday, October 29th. The shares were sold at an average price of $310.40, for a total transaction of $218,211.20. Following the completion of the sale, the vice president now directly owns 1,253 shares in the company, valued at $388,931.20. This represents a 35.94 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 0.53% of the stock is owned by corporate insiders.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.